Can Single Photon Emission Computed Tomography Myocardial Perfusion Imaging Monitor the Potential Benefit of Aggressive Treatment of Hyperlipidemia?

Overview

Journal J Nucl Cardiol

Specialty Cardiology & Vascular Diseases

Date 1998 Feb 10

PMID 9456198

Citations 3

Authors

R G Schwartz

T A PEARSON

Affiliations

Soon will be listed here.

Citing Articles

What is this image? 2017: Image 4 result : Improvement of ischemia with statin therapy.

Schwartz R J Nucl Cardiol. 2017; 25(1):22-24.

PMID: 29196912 DOI: 10.1007/s12350-017-1143-1.

Third Annual Mario S. Verani, MD, Memorial Lecture: The future of clinical nuclear cardiology.

Wackers F J Nucl Cardiol. 2005; 12(4):381-91.

PMID: 16084426 DOI: 10.1016/j.nuclcard.2005.05.004.

Beyond the cholesterol profile: monitoring therapeutic effectiveness of statin therapy.

Schwartz R J Nucl Cardiol. 2001; 8(4):528-32.

PMID: 11481576 DOI: 10.1067/mnc.2001.116847.

References

Falk E, Shah P, Fuster V . Coronary plaque disruption. Circulation. 1995; 92(3):657-71. DOI: 10.1161/01.cir.92.3.657. View

Blumenthal R, Becker D, Moy T, Coresh J, Wilder L, Becker L . Exercise thallium tomography predicts future clinically manifest coronary heart disease in a high-risk asymptomatic population. Circulation. 1996; 93(5):915-23. DOI: 10.1161/01.cir.93.5.915. View

Sellke F, Armstrong M, Harrison D . Endothelium-dependent vascular relaxation is abnormal in the coronary microcirculation of atherosclerotic primates. Circulation. 1990; 81(5):1586-93. DOI: 10.1161/01.cir.81.5.1586. View

. Coronary Drug Project report on clofibrate and niacin. Atherosclerosis. 1978; 30(3):239-40. View

Berman D, Germano G, Kiat H, Friedman J . Simultaneous perfusion/function imaging. J Nucl Cardiol. 1995; 2(3):271-3. DOI: 10.1016/s1071-3581(05)80065-0. View

HERD J, Ballantyne C, Farmer J, Ferguson 3rd J, Jones P, West M . Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol. 1997; 80(3):278-86. DOI: 10.1016/s0002-9149(97)00346-9. View

Pitt B, Mancini G, ELLIS S, Rosman H, Park J, McGovern M . Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation. J Am Coll Cardiol. 1995; 26(5):1133-9. DOI: 10.1016/0735-1097(95)00301-0. View

. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med. 1997; 336(3):153-62. DOI: 10.1056/NEJM199701163360301. View

. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344(8934):1383-9. View

10.

Corsini A, Raiteri M, Soma M, Gabbiani G, Paoletti R . Simvastatin but not pravastatin has a direct inhibitory effect on rat and human myocyte proliferation. Clin Biochem. 1992; 25(5):399-400. DOI: 10.1016/0009-9120(92)80024-b. View

11.

Selwyn A, Kinlay S, Libby P, Ganz P . Atherogenic lipids, vascular dysfunction, and clinical signs of ischemic heart disease. Circulation. 1997; 95(1):5-7. DOI: 10.1161/01.cir.95.1.5. View

12.

Osborne J, SIEGMAN M, Sedar A, Mooers S, Lefer A . Lack of endothelium-dependent relaxation in coronary resistance arteries of cholesterol-fed rabbits. Am J Physiol. 1989; 256(3 Pt 1):C591-7. DOI: 10.1152/ajpcell.1989.256.3.C591. View

13.

Miller D, Donohue T, Younis L, Bach R, Aguirre F, Wittry M . Correlation of pharmacological 99mTc-sestamibi myocardial perfusion imaging with poststenotic coronary flow reserve in patients with angiographically intermediate coronary artery stenoses. Circulation. 1994; 89(5):2150-60. DOI: 10.1161/01.cir.89.5.2150. View

14.

Zeiher A, Drexler H, Wollschlager H, Just H . Modulation of coronary vasomotor tone in humans. Progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation. 1991; 83(2):391-401. DOI: 10.1161/01.cir.83.2.391. View

15.

Shepherd J, Cobbe S, Ford I, Isles C, LORIMER A, Macfarlane P . Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995; 333(20):1301-7. DOI: 10.1056/NEJM199511163332001. View

16.

Yokoyama I, Ohtake T, Momomura S, Nishikawa J, Sasaki Y, Omata M . Reduced coronary flow reserve in hypercholesterolemic patients without overt coronary stenosis. Circulation. 1996; 94(12):3232-8. DOI: 10.1161/01.cir.94.12.3232. View

17.

Casino P, Kilcoyne C, Quyyumi A, Hoeg J, Panza J . The role of nitric oxide in endothelium-dependent vasodilation of hypercholesterolemic patients. Circulation. 1993; 88(6):2541-7. DOI: 10.1161/01.cir.88.6.2541. View

18.

. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet. 1994; 344(8923):633-8. View

19.

. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984; 251(3):351-64. DOI: 10.1001/jama.1984.03340270029025. View

20.

Jukema J, Bruschke A, van Boven A, Reiber J, Bal E, Zwinderman A . Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995; 91(10):2528-40. DOI: 10.1161/01.cir.91.10.2528. View